Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
Canaccord Genuity Trims PT on Anacor Pharmaceuticals (ANAC), Keeps Buy
January 30, 2013 10:09 AM ESTCanaccord Genuity lowered its price target on Anacor Pharmaceuticals (NASDAQ: ANAC) from $9 to $5 but is keeping a Buy rating following phase 3 data on Tavaborole.
The firm comments, "Maintaining BUY but lowering target to $5 from $9 as tavaboroles potential in onychomycosis becomes... More
Anacor Pharma (ANAC) Reports Positive P-3 Data on Tavaborole for Onychomycosis
January 29, 2013 7:10 AM ESTAnacor Pharmaceuticals (NASDAQ: ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high... More